MedTrace Logo

Dexamethasone in Total Knee Arthroplasty

NCT05018091 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 404

Last updated 2025-08-03

No results posted yet for this study

Summary

The purpose of this study is to determine the most efficacious and safest dexamethasone dose given intraoperatively during total knee arthroplasty that reduces postoperative opioid consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative complications.

Conditions

  • Total Knee Arthroplasty

Interventions

DRUG

Dexamethasone 4mg

4mg intravenous dexamethasone, administered shortly after induction of anesthesia

DRUG

Dexamethasone 8 Mg/mL Injectable Suspension

8mg intravenous dexamethasone, administered shortly after induction of anesthesia

DRUG

Dexamethasone 16mg

16mg intravenous dexamethasone, administered shortly after induction of anesthesia

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-28
Primary Completion
2025-01-01
Completion
2025-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05018091 on ClinicalTrials.gov